Literature DB >> 33415016

A novel prognostic scoring model for newly diagnosed FLT3-ITD-positive acute myeloid leukemia.

Yi Zhang1,2,3, Bi-De Zhao4, Cheng-Cheng Wang5, Yun-Gui Wang1,2,3, Hua-Feng Wang1,2,3, Jing-Han Wang1,2,3, Li-Xia Liu5, Feng Lou5, Shan-Bo Cao5, Xiao-Xia Hu6, Ai-Jie Huang6, Jian-Min Yang6, Hai-Tao Meng1,2,3, Wen-Juan Yu1,2,3, Hong-Yan Tong1,2,3, Jian-Min Wang6, Jie Jin1,2,3.   

Abstract

FMS-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD) is one of the most common somatic mutations in acute myeloid leukemia (AML). However, the molecular structure characteristics and widely accepted prognostic factors for FLT3-ITD are still not well described. This study aimed to retrospectively examine 81 patients with FLT3-ITD-positive AML diagnosed and treated at the First Affiliated Hospital of Zhejiang University from December 2013 to March 2018 using the next-generation sequencing 185-gene platform. High variant allele frequency (VAF) [> 0.48, P = 0.0089 for overall survival (OS), P = 0.13 for relapse-free survival (RFS)], multiple ITDs (> 1 ITDs, P = 0.011 for OS, P = 0.033 for RFS) and longer insertion length (> 69 bp, P = 0.14 for OS, P = 0.0078 for RFS) predicted poor survival. The study further proposed an easily applicable scoring model for OS using the Least Absolute Shrinkage and Selector Operation (LASSO) Cox regression model. Also, an independent cohort of 30 patients was used for external model validation. The mode was expressed as follows: 0.659 × FLT3-ITD VAF + 0.375 × FLT3-ITD number + 0.807 × Age + 0.688 × DNMT3A + 1.939 × U2AF1 (FLT3-ITD VAF > 0.48 scored 1; FLT3-ITD number scored 1 if carried 1 ITD, 2 if carried ≥ 2 ITDs; age > 44 years scored 1, the presence of DNMT3A or U2AF1 scored 1; 0 for other conditions). It categorized patients into low-risk (L-R, score < 1, n = 20) and high-risk (H-R, score ≥ 1, n = 61) groups based on the risk score with a significant difference in survival (3-year OS, P < 0.0001; 3-year RFS, P = 0.0005). A prognostic nomogram that integrated these five factors was developed with a concordance index calculation [OS: 0.68, 95% CI (0.64-0.72)]. AJCR
Copyright © 2020.

Entities:  

Keywords:  Acute myeloid leukemia; FLT3-ITD; LASSO cox regression; next-generation sequencing; prognosis

Year:  2020        PMID: 33415016      PMCID: PMC7783775     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  25 in total

1.  Molecular analysis of different FLT3-ITD mutations in acute myeloid leukemia.

Authors:  Olga Blau; Rimma Berenstein; Annette Sindram; Igor Wolfgang Blau
Journal:  Leuk Lymphoma       Date:  2012-09-05

2.  FLT3-ITD with DNMT3A R882 double mutation is a poor prognostic factor in Chinese patients with acute myeloid leukemia after chemotherapy or allogeneic hematopoietic stem cell transplantation.

Authors:  Shanhao Tang; Hongjie Shen; Xinliang Mao; Haiping Dai; Xiaming Zhu; Shengli Xue; Zixuan Ding; Jing Lu; Depei Wu; Xiaowen Tang
Journal:  Int J Hematol       Date:  2017-06-14       Impact factor: 2.490

Review 3.  Acute Myeloid Leukemia: The Good, the Bad, and the Ugly.

Authors:  Andrew Kuykendall; Nicolas Duployez; Nicolas Boissel; Jeffrey E Lancet; John S Welch
Journal:  Am Soc Clin Oncol Educ Book       Date:  2018-05-23

4.  DNMT3A co-mutation is required for FLT3-ITD as an adverse prognostic indicator in intermediate-risk cytogenetic group AML.

Authors:  Juan Ma; Jennifer Dunlap; Aleksandra Paliga; Elie Traer; Richard Press; Lisong Shen; Guang Fan
Journal:  Leuk Lymphoma       Date:  2017-11-22

Review 5.  FLT3-ITD and its current role in acute myeloid leukaemia.

Authors:  Francisco Alejandro Lagunas-Rangel; Venice Chávez-Valencia
Journal:  Med Oncol       Date:  2017-05-03       Impact factor: 3.064

Review 6.  The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.

Authors:  Daniel A Arber; Attilio Orazi; Robert Hasserjian; Jürgen Thiele; Michael J Borowitz; Michelle M Le Beau; Clara D Bloomfield; Mario Cazzola; James W Vardiman
Journal:  Blood       Date:  2016-04-11       Impact factor: 22.113

7.  Impact of FLT3-ITD allele ratio and ITD length on therapeutic outcome in cytogenetically normal AML patients without NPM1 mutation.

Authors:  Fang Chen; Junya Sun; Changxin Yin; Jiaying Cheng; Jinle Ni; Ling Jiang; Qiang Wang; Guopan Yu; Yongqiang Wei; Xiaoli Liu; Jing Sun; Bing Z Carter; Xuejie Jiang
Journal:  Bone Marrow Transplant       Date:  2019-10-23       Impact factor: 5.483

8.  Pattern and prognostic value of FLT3-ITD mutations in Chinese de novo adult acute myeloid leukemia.

Authors:  Song-Bai Liu; Qiao-Cheng Qiu; Xie-Bing Bao; Xiao Ma; Hong-Zhi Li; Yue-Jun Liu; Su-Ning Chen; Yao-Hua Song; De-Pei Wu; Sheng-Li Xue
Journal:  Cancer Sci       Date:  2018-11-14       Impact factor: 6.716

Review 9.  Targeting FLT3 mutations in AML: review of current knowledge and evidence.

Authors:  Naval Daver; Richard F Schlenk; Nigel H Russell; Mark J Levis
Journal:  Leukemia       Date:  2019-01-16       Impact factor: 11.528

10.  Prognosis and outcome of patients with acute myeloid leukemia based on FLT3-ITD mutation with or without additional abnormal cytogenetics.

Authors:  Shandong Tao; Chunling Wang; Yue Chen; Yuan Deng; Lixiao Song; Yuyue Shi; Lanlan Ling; Banghe Ding; Zhengmei He; Liang Yu
Journal:  Oncol Lett       Date:  2019-11-05       Impact factor: 2.967

View more
  1 in total

Review 1.  Role of Biomarkers in FLT3 AML.

Authors:  Jiao Wei; Ai-Min Hui
Journal:  Cancers (Basel)       Date:  2022-02-24       Impact factor: 6.639

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.